古老的药用植物迷香含有高效和同型选择性的KCNQ通道开放剂
Rían W Manville1, Derk Hogenkamp1, Geoffrey W Abbott2
1Bioelectricity Laboratory, Dept. of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Communications biology
|June 15, 2023
概括
迷香提取物和酸强烈地激活特定的KCNQ3/5通道,为神经系统疾病提供新的治疗潜力. 这项研究揭示了迷香的分子基础.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 电压通道 (Kv),特别是KCNQ亚家族,对于神经系统,心脏,肌肉和上皮功能至关重要.
- 异构的KCNQ通道复合体在大脑中可能具有不同的作用,但研究和治疗需要亚型特定的调节器.
- 迷香 (Salvia rosmarinus) 在治疗神经疾病方面具有悠久的药用历史.
研究的目的:
- 在迷香提取物中识别调节KCNQ通道活性的活性化合物.
- 描述迷香衍生KCNQ调节器的亚型选择性和作用机制.
- 探索这些化合物对神经系统疾病的治疗潜力.
主要方法:
- 在KCNQ通道上对迷香提取物和分离化合物的功能选.
- 在接和突变性研究中,以确定作用的分子机制.
- 对卡诺西克酸在不同KCNQ异构体上的疗效,强度和选择性的评估.
主要成果:
- 迷香提取物有效地激活异构体KCNQ3/5通道,对KCNQ2/3通道的影响较弱.
- 焦糖酸是一种迷香二烯,是一种强效的KCNQ3开放剂,耐PIP2耗尽,对KCNQ3/5比KCNQ2/3.3具有选择性.
- 肉酸和KCNQ3 S4-5链接剂阿尔金因之间的离子键解释了其强大的通道开放.
结论:
- 肉酸是KCNQ3/5通道的高度选择性开放剂,建议独特的治疗应用.
- 这些发现为迷香的传统神经治疗用途提供了分子基础.
- 这项研究突出了天然产品在发现离子通道新型调节器方面的潜力.
更多相关视频
07:19Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique
Published on: February 7, 2025
374
11:02Exploring Arterial Smooth Muscle Kv7 Potassium Channel Function using Patch Clamp Electrophysiology and Pressure Myography
Published on: September 14, 2012
15.6K
相关概念视频
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
01:26Voltage-gated Ion Channels
8.3K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
8.3K
01:20Antiepileptic Drugs: Potassium Channel Activators
218
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
218
01:24Non-gated Ion Channels
6.9K
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
6.9K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
575
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
575
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K